NICE guidance provides clear recommendations for GLP-1 use, which focus exclusively on glycaemic control in type 2 diabetes (NG28) and weight management in obesity (TA875 for semaglutide, TA664 for liraglutide)
MPGF ELISA AL-175
Not all prescribers who are now writing GLP-1 prescriptions have deep familiarity with the body composition literature that has emerged in the last three years
3-5 Microbial metabolites, such as secondary bile acids, short-chain fatty acids, lipopolysaccharide and others within the gut microbiota, trigger GLP-1 secretion
For researchers running their first cagrilintide protocol, the 5mg vial offers the best balance between cost efficiency and practical dosing flexibility
Semaglutide is a GLP-1 receptor agonist that, for many patients, provides sufficient appetite control and weight loss support without needing the dual-agonist approach that tirzepatide offers